Ventripoint Diagnostics Ltd. (TSXV:VPT; OTC:VPTDF) will exhibit at the 59th Annual Meeting of the Association for European Paediatric and Congenital Cardiology (AEPC), scheduled for May 12-16, 2026, in Padua, Italy. The event, hosted by the University of Padova, brings together over 1,000 specialists from 32 European countries and beyond, focusing on advanced cardiovascular imaging and artificial intelligence—areas where Ventripoint is making significant strides.
Ventripoint will share a booth with its European distributor, AngioPro, to engage with clinicians from the global congenital cardiology community. A key focus will be the VMS+ system, which enables tracking of cardiac function over time in congenital heart disease (CHD) patients. The 2020 ESC Guidelines for Adult Congenital Heart Disease, co-endorsed by AEPC, emphasize CHD as a lifelong condition requiring structured follow-up and identify echocardiography as the primary modality for longitudinal ventricular function assessment (Baumgartner et al., European Heart Journal, 2021; doi:10.1093/eurheartj/ehaa554).
Ventripoint’s priority for 2026 is accelerating integration of VMS+ into routine practice and improving care pathways for CHD patients. The latest release, VMS+ 4.0, streamlines workflows and reduces assessment time, making advanced cardiac analysis accessible at the point of care. From a patient’s first echocardiogram, VMS+ provides volumetric cardiac measurements equivalent to MRI, supporting clinical decisions and long-term management.
“AEPC represents the heart of the European congenital cardiology community, and we are proud to be part of it,” said Hugh MacNaught, President and CEO of Ventripoint. “VMS+ delivers fast, affordable, and accessible volumetric cardiac assessments with accuracy comparable to MRI – giving clinicians the confidence they need to manage their patients at every stage of life.”
